Cargando…

Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors

Detalles Bibliográficos
Autores principales:	Lu, Li, Zhu, Fen, Li, Yangguang, Kimpara, Shuichi, Hoang, Nguyet Minh, Pourdashti, Sheida, Rui, Lixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441016/ https://www.ncbi.nlm.nih.gov/pubmed/30926771 http://dx.doi.org/10.1038/s41408-019-0203-y

Ejemplares similares

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells
por: Li, Yangguang, et al.
Publicado: (2017)

An 11 years delayed diagnosis of primary pulmonary diffuse large B cell lymphoma
por: Yu, Jin-Yan, et al.
Publicado: (2019)

Neurolymphomatosis caused by diffuse large B-cell lymphoma presenting as isolated brachial plexopathy
por: Li, Heng, et al.
Publicado: (2019)

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors
por: Sommer, Eeva M., et al.
Publicado: (2013)

Relapsed Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type
por: Wu, Shaohua, et al.
Publicado: (2017)

Systemic diffuse large B-cell lymphoma with bilateral ciliary body involvement
por: Di, Yu, et al.
Publicado: (2020)

Roles of Akt and SGK1 in the Regulation of Renal Tubular Transport
por: Satoh, Nobuhiko, et al.
Publicado: (2015)

STAT3 Activation and Oncogenesis in Lymphoma
por: Zhu, Fen, et al.
Publicado: (2019)

Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication
por: Huo, Yu-Jia, et al.
Publicado: (2022)

Disseminated Invasive Mucormycosis Infection Following Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Ratios of Four STAT3 Splice Variants in Human Eosinophils and Diffuse Large B Cell Lymphoma Cells
por: Turton, Keren B., et al.
Publicado: (2015)

Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma
por: Tanba, Kazuna, et al.
Publicado: (2018)

Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients
por: Manfroi, B., et al.
Publicado: (2018)

Prioritizing Cancer Care in Low and Middle-Income Countries Using Delta Mortality-to-Incidence Ratios
por: Diehl, Thomas, et al.
Publicado: (2022)

Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma
por: Huo, Yu-Jia, et al.
Publicado: (2022)

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
por: Al-Sarayfi, Diana, et al.
Publicado: (2022)

Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma
por: Ludvigsen, Maja, et al.
Publicado: (2023)

Primary Small Intestinal Diffuse Large B-cell Lymphoma Masquerading as Crohn's Disease: A Case Report
por: Lu, Xiao-Hong, et al.
Publicado: (2017)

Oral CHOP‐like chemotherapy in 60–80 years‐old patients with diffuse large B‐cell lymphoma
por: Guidez, Stephanie, et al.
Publicado: (2019)

Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
por: Wang, Chaoyu, et al.
Publicado: (2023)

Clinical and prognostic features of primary retroperitoneal diffuse large B-cell lymphoma: a single-center experience in China
por: Liu, Xiao-Hong, et al.
Publicado: (2021)

A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications
por: El-Sharkawi, Dima, et al.
Publicado: (2023)

SGK1 mutation status can further stratify patients with germinal center B‐cell‐like diffuse large B‐cell lymphoma into different prognostic subgroups
por: Guo, Baoping, et al.
Publicado: (2022)

The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma
por: Li, Jiao, et al.
Publicado: (2022)

Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome
por: Richter, Julia, et al.
Publicado: (2019)

Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study
por: Park, Sohee, et al.
Publicado: (2023)

SKIN NODULES AS A PRESENTING FEATURE OF DIFFUSE LARGE B-CELL GASTRIC LYMPHOMA
por: Suresh Attili, V Satya, et al.
Publicado: (2008)

AKT-independent PI3-K signaling in cancer – emerging role for SGK3
por: Bruhn, Maressa A, et al.
Publicado: (2013)

JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis
por: Le, Kang, et al.
Publicado: (2021)

INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway
por: Chen, Ying, et al.
Publicado: (2018)

Expression profile of translation initiation factor eIF2B5 in diffuse large B-cell lymphoma and its correlation to clinical outcome
por: Unterluggauer, Julia J., et al.
Publicado: (2018)

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
por: Dührsen, Ulrich, et al.
Publicado: (2021)

The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling
por: Tactacan, Carole M., et al.
Publicado: (2015)

Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma
por: Hill, Brian T., et al.
Publicado: (2019)

STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma()
por: Tamma, Roberto, et al.
Publicado: (2019)

Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse
por: Ma, Jiao, et al.
Publicado: (2019)

Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation
por: Yao, Su, et al.
Publicado: (2017)

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
por: Zhu, Yanan, et al.
Publicado: (2022)

AKT and SGK kinases regulate cell migration by altering Scar/WAVE complex activation and Arp2/3 complex recruitment
por: Singh, Shashi Prakash, et al.
Publicado: (2022)

Lymphomatous Variant of Adult T-cell Leukemia/Lymphoma
por: Prathap, Priya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h3q8ipd6l3kolv6jh9hf0bdtbd